Education

1971-1974 Greece Arcadia High School, Rochester, New York

1974-1978 University of Buenos Aires, Faculty of Medicine, Buenos Aires, Argentina

1978-1981 University Hospital de Clinicas "José de San Martin", Buenos Aires, Argentina - Internal Medicine Residency

1981-1982 Scott & White Memorial Hospital, Temple, Texas - Pathology Internship

1982-1983 Wadley Institute of Molecular Medicine, Granville C. Morton Hospital, Dallas, Texas - Fellowship, Hematology/Oncology

1983-1984 University of Texas Health Science Center, Southwestern Medical School / Parkland Memorial Hospital, Dallas, Texas - Fellowship, Clinical and Research Hypertension

2007-2009 MBA, Texas Tech University, Lubbock, Texas

Current Position

1984-Present Private Practice, Internal Medicine and Hypertension, Carrollton, Texas

1984-Present Medical Director, Clinical Trials, Trinity Hypertension & Metabolic Research Institute, Carrollton, Texas :

1985-Present Attending Physician, Internal Medicine Department, Carrollton Regional Medical Center, Carrollton, Texas

Academic Position

2004-Present Associate Clinical Professor, Texas Woman's University. Dallas, Texas

2010-Present Clinical Assistant Professor, University of Texas Southwestern Medical School, Dallas, Texas

Hospital Positions

1982 Emergency Department Staff: Matagorda County Hospital, Bay City, Texas; Silsbee Doctor's Hospital, Silsbee, Texas; T.L. Goodnight Memorial Hospital, Caldwell, Texas; Grant Buie Memorial Hospital, Hillsboro, Texas; Newburn Memorial Hospital, Jacksonville, Texas; Fannin County Hospital, Bonham, Texas.

1983 St. Joseph's Hospital, Paris, Texas; Stevens Park Hospital, Dallas, Texas.

1984 Internal Medicine Department: Granville C. Morton Hospital, Dallas, Texas; Shiloh Park Hospital, Garland, Texas.

1985 Trinity Medical Center, Carrollton, Texas.

1986 Southwest Dallas Hospital, Dallas, Texas.

Appointments

1979 English/Spanish Translator, Merck, Sharp, & Dohme Laboratories, Buenos Aires, Argentina.

1980 University of Buenos Aires, Argentina, Clinical Instructor, Medical English Department.

1982-1986 Visiting Physician, Adult Alcohol Rehabilitation Program, Salvation Army, Dallas, Texas.

1983 President, House Staff Association, Granville C. Morton Cancer and Research Hospital, Dallas, Texas.

1983-1985 Sunshine Kids Foundation, Houston, Texas - Founding Staff Physician.

1984 Texas State Delegate to the American Medical Association, RPS Section's Meeting, Chicago, Illinois.

1983-1984 Treasurer, Dallas Society of Clinical Hypnosis, Dallas, Texas.

1984 Texas Delegate to the American Medical Association, RPS Section Meeting, Honolulu, Hawaii.

1984-1985 Resident Representative, Board of Trustees, Educational Commission for Foreign Medical Graduates.

1984-1985 Health Officer, Dallas County Health Department, Lew Sterrett Correctional Facility, Dallas, Texas.

1984-1986 Medical Director, Drug Abuse Rehabilitation Program, “Help is Possible," Dallas, Texas.

1984-1986 Alternate Delegate, Dallas County Medical Society, Dallas, Texas.

1987-2002 Delegate, Dallas County Medical Society, Dallas, Texas.

1985-1987 Chairman, Institutional Review Board, Trinity Medical Center, Carrollton, Texas.

1985-1987 Founding Board Member, Northwest Medicare IPA, Farmers Branch, Texas.

1985-1986 Chief of Staff, Internal Medicine Department, Trinity Medical Center, Carrollton, Texas.

1986-1987 Special Friends Foundation, Staff Physician.

1986-1987 Chairman, Board of Trustees, DARCO Drug Service, Inc. Drug Rehabilitation Program, Dallas, Texas.

1986-1987 Texas State Delegate to the American Medical Association, Young Physicians Section.

1986-1987 Advisory Board, Technical Internship Program, Carrollton/Farmers Branch Independent School District.

1986-1987 First Western National Bank Advisory Board, Carrollton, Texas.

1986-1989 Texas Industrial Accident Board, Medical Arbitration, District 4.

1987 Texas Medical Foundation Physicians Advisor.

1987 Chairman, Young Physician Section, Texas Medical Association.

1987-1988 Board of Trustees, American College of International Physicians.

1989 Reviewer, Geriatric Cardiovascular Medicine.

1991 Reviewer, Journal of Clinical Research and Pharmacoepidemiology.

1994 Reviewer, Journal of Human Hypertension.

1996 Editorial Board, Dallas Medical Journal.

1997-2008 Chairperson, Editorial Board, Dallas Medical Journal.

2004. Reviewer, Journal Drugs.

2005 Reviewer, American Journal of Hypertension.

2005 Reviewer, Journal of Clinical Epidemiology.

2008 Member, Communications Committee, Dallas County Medical Society.

2009 Reviewer, Journal of the Renin-Angiotensin Aldosterone System.

2025 Reviewer, New England Journal of Medicine.

Special Training

1980-1981 Research Assistant, Hypertension Division, Vth Cathedra of Internal Medicine, University Hospital de Clinicas, "José de San Martin," Buenos Aires, Argentina.

1984-1990 Instructor, "Advanced Cardiac Life Support."

1986-Present Investigator - Phase II-IV Clinical Research Studies.

Society Memberships

1982 Dallas County Medical Society; Texas Medical Association; American Medical Association; National Association of Residents and Interns; Inter-American College of Physicians and Surgeons.

1983 Dallas Society of Clinical Hypnosis.

1983 North Texas Association of Latin American Physicians.

1984 American College of Emergency Physicians; The New York Academy of Sciences; The Hispanic American Society of Hypertension.

1985 Texas Society of Internal Medicine; The American Society of Internal Medicine; Associates of Clinical Pharmacology.

1986 American College of Medicine; The American Society of Hypertension; Argentine Intra-University Society of Internal Medicine.

1987 American College International Physicians; American College of Physicians.

1988 American College of Clinical Pharmacology; Inter-American Society of Hypertension; American Society for Clinical Pharmacology and Therapeutics. Henry A. Punzi, MD, FCP, FASH | Z

1989 Member, Council for High Blood Pressure Research, American Heart Association.

2011 Fellow, American Society of Hypertension.

Committees

1983 Pain Committee, Granville C. Morton Cancer and Research Hospital, Dallas, Texas.

1983-1984 Texas Political Action Committee, Board Member; Texas Medical Association, Committee on Cancer, Resident Representative.

1983 Credentials Committee, Resident Physician Section, American Medical Association Interim Meeting, Los Angeles, California.

1984 Tellers Committee, Resident Physician Section, American Medical Association, Chicago, Illinois.

1983-1985 Resident Representative, American Medical Association, Ad Hoc Committee on Foreign Medical Graduates.

1985-1986 Member, American Medical Association Ad Hoc Committee on Foreign Medical Graduates.

1985 Tellers Committee, Texas Medical Association, House of Delegates Meeting, San Antonio, Texas.

1986-1987 Chairman, Health Services Committee, Metrocrest Chamber of Commerce.

1986-1989 Texas Medical Association, Committee on Association Insurance Programs.

1986 Texas Medical Association, Steering Committee, Young Physicians Section.

1987 Pharmacy and Therapeutics Committee, Trinity Medical Center, Carrollton, Texas.

1987 Medical Records and Utilization Review Committee, Trinity Medical Center, Carrollton, Texas.

1987 Fundacion Argentina Para Estudios en Hipertension Arterial, Buenos Aires, Argentina - Scientific and Educational Advisory Committee.

1987 Reference Committee Legislation, Texas Medical Association, Interim Session, House of Delegates.

1989 Texas Medical Association Insurance Trust.

1990 Interprofessional Mental Health Liaison Committee for Texas.

1990 Advisory Board, Willow Bend Polo Club, Dallas, Texas.

1991 Ethics Committee, Trinity Medical Center, Carrollton, Texas.

1991 Texas Medical Association, Reference Committee on Constitution and Bylaws.

1992 Texas Medical Association, Reference Committee on Public Health and Scientific Affairs.

1998 Chairperson, Institutional Review Board, Trinity Medical Center.

2010 National Institute of Health SPRINT Study - Member of the Recruitment, Retention and Adherence Subcommittee.

Honors And Awards

1980 Graduated with Honors, University of Buenos Aires, Faculty of Medicine, Buenos Aires, Argentina. Appointed Master of Ceremonies of First Gala Graduate Party, University of Buenos Aires, Faculty of Medicine.

1983-1984 Guest Host, Television Talk Show, "Ayuda e Informacion," Channel 33, Dallas, Texas.

1984 Pfizer Laboratories, Speakers Program, "Hypertension."

1984 Medical Columnist, Newspaper, "La Aurora,” Dallas, Texas.

1984 Guest Lecturer, University of Buenos Aires Faculty of Medicine, Buenos Aires, Argentina.

1985 American Medical Association, Certificate of Recognition for Outstanding Service in Resident Physician Section.

1986 Volunteer Ski Instructor, Handicap Skiing Program, Winter Park, Colorado.

1986 Recognition for Outstanding Service in Technical Internship Program by Board of Directors of Carrollton/Farmers Branch Independent School District by Resolution passed on June 12, 1986.

1986 Guest Speaker, Television Talk Show, "Texas Accents," Channel 33, Dallas, Texas.

1986 E.R. Squibb Laboratories, Speakers Program, "Hypertension."

1986 Guest Lecturer in Universities of Buenos Aires, Cordoba and Bahia Blanca, Faculty of Medicine, Argentina.

1986 Texas Medical Association, Certificate of Appreciation for outstanding service performed in the Committee on Association Insurance Programs.

1987 Knoll Pharmaceutical Speakers Program, "Hypertension."

1987 Smith Kline and French Pharmaceutical Speakers Program, "Hypertension."

1987 Guest Lecturer, "Hypertension," University of Buenos Aires, Argentina, Fourth University Congress of Internal Medicine, Rosario, Argentina.

1988 Television Interview on Diabetes Mellitus for Channel 49, Dallas, Texas.

1988 A.H. Robbins, Speakers Program.

1988 Texas Medical Association Award, Outstanding Contribution to the Physician Outreach Program.

1988 Abstract Presentation - American Society of Hypertension Annual Meeting, New York, New York: Evaluation of efficacy and safety of Cilazapril versus Inderal LA in patients with essential hypertension.

1988-1989 Cecil Smith Award for the Most Promising Polo Player, Willow Bend Hunt and Polo Club, Plano, Texas.

1989 Outstanding Service and Involvement in the Partnership in Education Program, Metrocrest Chamber of Commerce and Carrollton Farmers Branch Independent School District and Independent Schools.

1989-1990 Most Improved Player, Willow Bend Hunt and Polo Club, Plano, Texas.

1990-1991 Sportsmanship Award, Willow Bend Hunt and Polo Club, Plano, Texas.

1991-Present Reviewer for: Journal of Clinical Hypertension; Hypertension; The American Journal of Hypertension; Journal of Human Hypertension; Experimental Hypertension; International Journal of Hypertension; Integrated Blood Pressure Control; Therapeutic Advances in Cardiovascular Disease; Drugs; Expert Review of Cardiovascular Therapy; Journal of Clinical Research and Pharmacoepidemiology; Journal of Geriatric Cardiovascular Medicine; Aging and Drugs; Cardiovascular Expert Review; Journal of Cell Adhesion and Migration; Drugs of Today; Cell Biochemistry and Function; Cardiovascular Diagnosis and Therapy; Journal of the Renin-Angiotensin Aldosterone System.

1992 "Who's Who Among Rising Young Americans," recognized for achievements in American Society and business.

2002 FAA Private Pilots License.

2004 FAA Instrument Rating.

2005 FAA Multiengine Rating.

2010-2018 Host, "Su Salud" Radio Show, La Bonita 106.7, Dallas, Texas.

2011 Academic Editor, International Journal of Hypertension.

2015-2018 Board of Directors, Consortium of South East Hypertension Centers.

2015-Present The Open Hypertension Journal, Editorial Board Member.

2015-Present Board of Directors, Inter-American Society of Hypertension.

2017 Greece Arcadia Sports Hall of Fame Inductee: First U.S.-born professional soccer player in Argentina.

2018 Host, "Su Salud" Radio Show, La Nueva 106.5, Dallas, Texas.

Licensure And Certifications

12/20/1980 Buenos Aires, Argentina - National Matriculation.

01/12/1981 ECFMG Certificate, Dallas, Texas.

02/20/1982 Texas Licensure, Federal Licensing Examination.

1988 Fellow, American College of Clinical Pharmacology.

2009 FAA Designated Aviation Medical Examiner.

2010 Fellow, American Society of Hypertension.

2014 Civil Air Patrol Health Services Officer: Rank of Captain.

2015 FAA Designated Senior Aviation Medical Examiner.

Certifications

Board Eligible: Clinical Pharmacology

Publications

1. Feldstein CA, Punzi HA. The comparison of hydrochlorothiazide and Hydrochlorothiazide with Metoprolol in patients with essential hypertension during stress testing. Hispanic-American Journal of Hypertension. Aug 1983.

2. Kaplan NM, Punzi HA. Diabetes and hypertension: guidelines for treatment. Clinical Diabetes. 1984; 2:25-35.

3. Ram CVS, Punzi HA, Chia BL. Three agents for resistant hypertension: how do they compare? Modern Medicine. 1984; 52(9):88-105.

4. McPhaul M, Punzi HA, Sandy A, Borgenelli M, Rude R, Kaplan NM. Snuff induced hypertension in Pheochromocytoma. JAMA. 1984; 252:2860-2862.

5. Punzi HA. Tratamiento de la Hipertension Refractaria. In: Kaplan NM, Feldstein CA (Eds). TERAPEUTICA CARDIOVASCULAR. Buenos Aires: Panamericana; 1986:128.

6. Marculies M, Punzi HA, Voto LS. Hipertension y Embarazo. In: Kaplan NM, Feldstein CA (Eds). TERAPEUTICA CARDIOVASCULAR. Buenos Aires: Panamericana; 1986:123-128.

7. Feldstein CA, Punzi HA. Drogas Comunmente Utilizada en Terapeuticas Cardiovascular. In: Kaplan NM, Feldstein CA (Eds). TERAPEUTICA CARDIOVASCULAR. Buenos Aires: Panamericana; 1986:571-610.

8. Punzi HA, Kaplan NM. Therapy of Hypertension in the diabetic patient: Pharmacologic Intervention. Cardiovascular Review and Reports. 1987; 8(10):61-63.

9. Punzi HA, Kaplan NM. Therapy of Hypertension in the diabetic patient: Non-Pharmacologic Intervention. Cardiovascular Review and Reports. 1987; 8(11):37-40.

10. Feldstein CA, Boshini P, Punzi HA. Renovascular Hypertension in a Major University Teaching Hospital. Presented to 2nd Inter-University Congress of Internal Medicine, Argentina; Nov 1987.

11. Punzi HA, Mills J, Lara S. Evaluation of efficacy and safety of Cilazapril versus Inderal LA in patients with essential hypertension. Am J Hypertens. 1988; 1(3, 2):294.

12. Punzi HA, Mills JK. Comparison of efficacy, safety, and tolerability of benazepril to propranolol as add on therapy to hydrochlorothiazide in moderate to severe hypertension. Am J Hypertens. 1989; 2(5, 2):512A.

13. Punzi HA, Flamenbaum W (Series Eds). CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol 1. Mount Kisco, NY: Futura Publishing; 1989.

14. Punzi HA. Hypertension and Concomitant Diseases. In: CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol 1. Futura Publishing; 1989:247-268.

15. Punzi HA, Flamenbaum W. The Future. In: CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol 1. Futura Publishing; 1989:395-398.

16. Punzi HA, Zusman R. Specific Angiotensin-Converting Enzyme Inhibitors, Captopril. In: Messerli FH (Ed). CARDIOVASCULAR DRUG THERAPY. WB Saunders; 1990:770-791.

17. Punzi HA, Mills JK. A Randomized, Double-Blind, Placebo-Controlled parallel Study of Antihypertensive Response to Celiprolol Hydrochloride. J Clin Pharmacol. 1991; 31(9):842.

18. Punzi HA, Flamenbaum W (Series Eds). CLINICAL CARDIOVASCULAR THERAPEUTICS: CARDIAC ARRHYTHMIAS: A PRACTICAL APPROACH. Vol 2. Futura Publishing; 1991.

19. Punzi HA, Flamenbaum W (Series Eds). CLINICAL CARDIOVASCULAR THERAPEUTICS: CORONARY HEART DISEASE AND RISK FACTORS. Vol 3. Futura Publishing; 1991.

20. Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing diltiazem SR and hydrochlorothiazide combination to monotherapies. J Hum Hypertens. 1992:133-138.

21. Punzi HA. Cilazapril versus Propranolol LA in patients with essential hypertension. J Clin Res Pharmacoepidemiol. 1992; 6:303-311.

22. Punzi HA, Germino FW, Lastra J, Pool P, Spinowitz B, Smith W, Mills D. Pilot study evaluating cough profile of fosinopril sodium in patients with previous ACE inhibitor cough. J Hypertens. 1993; 6(S).

23. Germino FW, Lastra J, Pool P, Punzi HA, et al. Evaluating the Cough Profile of Fosinopril Sodium in Hypertensive Patients. Curr Ther Res. 1993; 54(S):469-475.

24. Punzi HA. Safety Update: Focus on Cough. Am J Cardiol. 1993; 72:1H-4H.

25. White WB, Punzi HA, MacIntyre JM, Verburg KM, Anders RJ. Ambulatory vs clinic blood pressure measurements in Verapamil GITS efficacy study. Am J Hypertens. 1994; 7(4, 2):44A.

26. Punzi HA, Zusman R. Specific Angiotensin-Converting Enzyme Inhibitors, Captopril. In: Messerli FH (Ed). CARDIOVASCULAR DRUG THERAPY. 2nd ed. WB Saunders; 1996:726-742.

27. Punzi HA, Novrit BA, Trandolapril/Verapamil Multicenter Study Group. Trandolapril in combination with verapamil SR in severe essential hypertension. Am J Hypertens. 1996; 9(4, 2):143A.

28. Punzi HA, Novrit BA, Trandolapril/Verapamil Multicenter Study Group. Treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. J Hum Hypertens. 1997; 11:477-481.

29. Punzi HA, Rhodes MM. Comparison of repeated office blood pressure measurements versus 24 hr. ambulatory blood pressure monitoring. Am J Hypertens. 1998; 11(4, 2):512A.

30. Masonson HN, Punzi HA, Neutel JM, et al. CS-866 double-blind study using ambulatory blood pressure monitoring. Am J Hypertens. 1998; 11(4, 2):77A.

31. Punzi HA. Why ambulatory blood pressure monitoring? Am J Health Syst Pharm. 1998; 55(N22 933):S12-S16.

32. Punzi HA, Noveck R, Weiss Rj, et al. Differences in long-acting calcium channel blockers on ambulatory blood pressure: Nisoldipine ER vs amlodipine. Blood Press Monit. 1998; 3(4):267-272.

33. Gradman AH, Gray J, Maggiacomo F, Punzi HA, White WB. Evaluation of eprosartan used once-daily in systemic hypertension. Clin Ther. 1999; 21(3):442-453.

34. Punzi HA, Punzi CF. Isolated systolic hypertension. In: Messerli FH (Ed). CARDIOVASCULAR CLINICAL CASES. PAN Communications; 2002; 3:168-173.

35. Punzi HA, Punzi CF. 13-week study of eprosartan mesylate (600 mg or 1200 mg) in isolated systolic hypertension. Am J Hypertens. 2003; 16(5 P 2):127A.

36. Punzi HA, Punzi CF. Metabolic issues in the ALLHAT study. Curr Hypertens Rep. 2004; 6:106-110.

37. Punzi HA, Punzi CF, Eprosartan International Investigators. Eprosartan in isolated systolic hypertension. J Hum Hypertens. 2004; 18:655-661.

38. Punzi HA, Punzi CF. ABPM study of Teveten (eprosartan mesylate) 600 mg and 1200 mg in essential hypertension. Am J Hypertens. 2005; 18(5 P 2):93A.

39. White WA, Punzi HA, Neutel J, et al. Telmisartan plus HCTZ (80/25 mg) vs valsartan plus HCTZ (160/25 mg) in Stage 1 & 2 hypertension. Am J Hypertens. 2005; 18(5 P 2):97A.

40. Punzi HA, Punzi CF. COMPARE Study: Tarka vs Lotrel in Stage I-II hypertension using ABPM. Am J Clin Hypertens. 2006; 8(5):A56-A57.

41. Punzi HA, Punzi CF. Comparison of Sular (nisoldipine) vs Norvasc (amlodipine) utilizing ABPM in Stage I & II hypertension. Am J Clin Hypertens. 2006; 8(5):A56.

42. White WA, Punzi HA, Murwin D, et al. Telmisartan vs Valsartan in combination with HCTZ 25 mg for hypertension. J Clin Hypertens. 2006; 8(9):626-633.

43. Kereiakes D, Neutel J, Punzi HA, et al. Efficacy of Olmesartan/HCTZ vs benazepril/amlodipine in Stage 2 hypertension. J Clin Hypertens. 2007; 9(5 Supp A):A168.

44. Neutel J, Kereiakes D, Punzi H, et al. Optimal combination therapy: Benazepril/amlodipine vs olmesartan/HCTZ study design. J Clin Hypertens. 2007; 9(S Supp A):A172-A173.

45. Neutel J, Kereiakes D, Punzi H, et al. Blood pressure goal attainment with olmesartan/HCTZ or benazepril/amlodipine. J Clin Hypertens. 2007; 9(5 Supp A):A173.

46. Punzi H, Kereiakes D, Neutel J, et al. Effect of olmesartan and benazepril on plasma renin activity in Stage 2 hypertension. J Clin Hypertens. 2007; 9(5 Supp A):A168.

47. Kereiakes D, Neutel J, Punzi HA, et al. Efficacy and Safety of Olmesartan/HCTZ Compared with Benazepril/Amlodipine. Am J Cardiovasc Drugs. 2007; 7(5):361-372.

48. Punzi HA, Kereiakes D, Xu J, et al. Olmesartan/HCTZ and benazepril/amlodipine efficacy stratified by age and gender. J Clin Hypertens. 2008; 10(S Supp A):A32.

49. Neutel J, Punzi HA, Xu J, et al. Olmesartan/HCTZ vs benazepril/amlodipine in black and non-black patients with Stage 2 hypertension. J Clin Hypertens. 2008; 10(5 Supp A):A28.

50. Neutel JM, Germino WF, Punzi HA, et al. Efficacy and safety of PS 433540 in human subjects with hypertension. Circulation. 2008; 118S:886.

51. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther. 2009; 7(3):229-239.

52. Kawata AK, Revicki DA, Thakkar R, ..., Punzi HA, Padley RJ. Flushing Assessment Tool (FAST) in niacin therapy. Clin Drug Investig. 2009: 29(4):215-229.

53. Littlejohn T, Graff A, Majul CR, Punzi H, et al. Telmisartan + amlodipine in North and Latin American hypertensive patients. J Clin Hypertens. 2009; 11(4 Supp A):A36.

54. Littlejohn T, Punzi H, Webster D, et al. Telmisartan + amlodipine in treatment-naive and previously treated patients. J Clin Hypertens. 2009; 11(4 Supp A):A37.

55. Littlejohn T, Graff A, Punzi H, et al. Telmisartan + amlodipine efficacy according to race. J Clin Hypertens. 2009; 11(4 Supp A):A37,

56. Neutel J, Kereiakes DJ, Punzi H, et al. Amlodipine/olmesartan titration regimen assessed by 24h ABPM. J Clin Hypertens. 2009; 11(4 Supp A):A129.

57. Neutel J, Punzi H, Shojaee A, et al. Amlodipine/olmesartan titration regimen by baseline hypertension stage. J Clin Hypertens. 2009; 11(4 Supp A):A130.

58. Punzi H, Lewin A, Shojaee A, et al. Amlodipine/olmesartan titration regimen on blood pressure goal achievement. J Clin Hypertens. 2009; 11(4 Supp A):A133.

59. Punzi H, Lewin A, Littlejohn T, et al. Amlodipine/olmesartan titration in patients with or without diabetes. J Clin Hypertens. 2009; 11(4 Supp A):A134.

60. Punzi H, Kereiakes DJ, Shojaee A, et al. Amlodipine/olmesartan titration by age and gender. J Clin Hypertens. 2009; 11(4 Supp A):A134.

61. Punzi HA, Punzi CF. Water displacement technique to differentiate calcium antagonist-induced lower extremity edema. J Clin Hypertens. 2009; 11(4 Supp A):A135.

62. Punzi HA, Neutel JM, Kereiakes Dj, et al. The AZTEC study: Amlodipine and olmesartan in hypertension. Ther Adv Cardiovasc Dis. 2010; 4(4):209-221.

63. Punzi HA, Lewin A, Lukic T, et al. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension. Ther Adv Cardiovasc Dis. 2010; 4(6):349-357.

64. Weir MR, Punzi HA, Flack J, et al. Olmesartan medoxomil vs losartan potassium in stage 1 and 2 hypertension. Postgrad Med. 2011; 123(1):80-87.

65. Punzi HA. Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide. Integr Blood Press Control. 2011; 4:73-83.

66. Punzi HA, Shojaee A, Waverczak WF, Maa JF. Amlodipine and olmesartan in hypertensive patients with diabetes and obesity. J Clin Hypertens. 2011; 13(6):422-430.

67. Papademetriou V, Tsioufis C, Gradman A, Punzi HA. Difficult-to-Treat or Resistant Hypertension: Etiology & Therapies. Int J Hypertens. 2011; 2011:1-4.

68. Punzi HA, Punzi CF. Nebivolol/amlodipine vs metoprolol/amlodipine in subjects with hypertension and pedal edema. J Clin - Hypertens. 2012; 14(Supp 1):A65.

69. Punzi HA, Lewin A, Wei LJ, Chavanu KJ. Olmesartan vs losartan in naive vs previously treated subjects. Adv Ther. 2012; 29(6):524-537.

70. Punzi HA, Shojaee A, Maa JF. Fixed-dose amlodipine/olmesartan + HCTZ in Hispanic and non-Hispanic patients. Ther Adv Cardiovasc Dis. 2012; 6(4):149-161.

71. Punzi HA, Dahlof B, Webster D, et al. Telmisartan and amlodipine in treatment-naive and previously treated patients. Clin Exp Hypertens. 2012.

72. Lewin A, Punzi HA, Luo X, Stapff M. Nebivolol in individuals with systolic Stage II hypertension. Clin Ther. 2013.

73. Punzi HA, Punzi CF. Fixed dose triple drug therapy (olmesartan/amlodipine/HCTZ) as replacement therapy. J Clin Hypertens. 2013; 15(1):A57.

74. Ferrario CM, Punzi HA, Moore MA. ARBs in Hypertension: Focus on Olmesartan. MacMillan Medical Communications; 2013.

75. Ferrario CM, Punzi HA, Panjabi S, Jessup JA. OLMESARTAN IN HYPERTENSION. Physician Quick Reference Series. MacMillan Medical Communications; 2013.

76. Punzi H. CHAMPION study: Olmesartan/amlodipine/HCTZ in patients not at goal. Ther Adv Cardiovasc Dis. 2014; 8(1):12-21.

77. Neutel J, Giles TD, Punzi HA, et al. Long-Term Safety of nebivolol and valsartan combination therapy. J Am Soc Hypertens. 2014; 8(12):915-920.

78. Varagic J, Punzi H, Ferrario CM. Clinical utility of nebivolol/valsartan fixed-dose combinations. Integr Blood Press Control. 2014; 7:61-70.

79. Punzi HA. TANDEM study: Nebivolol vs metoprolol as dual therapy with amlodipine. J Am Soc Hypertens. 2014; 8(4):e27.

80. Punzi HA. Combination therapy with nebivolol/amlodipine vs metoprolol/amlodipine on 24-hr ABPM. J Am Soc Hypertens. 2015; 9(4S):e24.

81. The SPRINT Research Group (Punzi HA et al.). A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-2116.

82. Giles TD, Punzi H, Mallick M, Ferguson W, Patel M. Placebo response in Hispanics vs non-Hispanics in nebivolol trials. J Am Soc Hypertens. 2016; 10(4S):e62-e63.

83. Ishak J, Rael M, Punzi H, et al. Additivity of Nebivolol/Valsartan Single-Pill Combination. J Am Soc Hypertens. 2016; 10(Supp 1):05-026.

84. Rodriguez CJ, Still CH, Garcia KR, Wagenknecht L, White S, Bates JT, Del Cid MV, Lioudis M, Barrera NL, Moreyra A, Punzi H, Ringer RY, Cushman WC, Contreras G, Servilla K, Rocco M. Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic Blood Pressure Intervention Trial. J Clin Hypertens. 2016; 1-10.

85. Ishak J, Rael M, Punzi H, Gradman A, Anderson L, Patel M, Ali S, Ferguson W, Neutel J. Additivity of Nebivolol/Valsartan Single-Pill Combinations versus Other Single-Pill Combinations for Hypertension. J Clin Hypertens. 2018; 20:143-149.

86. Basile J, Egan B, Punzi H, Ali S, Li Q, Patel M, Neutel J. Risk of Hospitalization for Cardiovascular Events with Beta-Blockers in Hypertensive Patients: A Retrospective Cohort Study. Cardiol Ther, 2018.

87. Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, Jotwani V, Haley WE, Ishani A, Lash JP, Neyra JA, Punzi H, Rastogi A, Riessen E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhatt UY, Shlipak MG, Ix JH, Estrella MM. Markers of Kidney Tubule Cell Function and Injury and Risk of Subsequent Acute Kidney Injury: The SPRINT Trial. Kidney Int. 2019; 96(2):470-479.

88. Garimella PS, Lee AK, Ambrosius WT, Bhatt U, Cheung AK, Chonchol M, Craven T, Hawfield AT, Jotwani V, Killeen A, Punzi H, Sarnak MJ, Wall BM, Ix JH, Shlipak MG. Markers of Kidney Tubule Function and Risk of Cardiovascular Disease Events and Mortality in the SPRINT Trial. Eur Heart J. June 2019.

89. Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, Jotwani V, Haley WE, Ishani A, Lash JP, Neyra JA, Punzi H, Rastogi A, Riessen E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhatt UY, Shlipak MG, Ix JH, Estrella MM. The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury. Kidney Int. 2019; 96(2):470-479.

90. Jotwani VK, Lee AK, Estrella MM, Katz R, Garimella PS, Malhotra R, Rifkin DE, Ambrosius W, Freedman BI, Cheung AK, Raphael KL, Drawz P, Neyra JA, Oparil S, Punzi H, Shlipak MG, Ix JH, for the SPRINT Research Group. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among SPRINT Participants with Chronic Kidney Disease. Am J Nephrol. 2019; 49(5):346-355.

91. Dolui S, Detre JA, Cho MB, Haley WE, Launer LJ, Punzi HA, Rastogi A, Still CH, Weiner DE, Wright JT Jr, Williamson JD, Wright CB, Nasrallah IM. Effect of Intensive versus Standard Blood Pressure Control on Cerebral Blood Flow in SPRINT. Alzheimer's & Dementia. 2020; 16(S4).

92. Jovanovich A, Ix J, Punzi H, et al. Falls and Frailty in SPRINT. J Am Geriatr Soc. 2021; 69(2):467-473.

93. Ginsberg C, Ix JH, Punzi H, et al. The Effects of Intensive Blood Pressure Control on Markers of Mineral Metabolism in SPRINT. Clin J Am Soc Nephrol. 2020; 15(6):852-854.

94. Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, Rastogi A, Cheung AK, Freedman BI, Punzi H, Rocco MV, Ix JH, Shlipak MG. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020; 15:349-358.

95. Jotwani V, Garimella PS, Katz R, Malhotra R, Bates J, Cheung AK, Chonchol M, Drawz PE, Freedman BI, Haley WE, Killeen AA, Punzi H, Sarnak MJ, Segal MS, Shlipak MG, Ix JH, SPRINT Research Group. Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants. Am J Nephrol. 2020; 51(10):797-805.

96. Beddhu S, Boucher RE, Sun J, Balu N, Chonchol M, Navaneethan S, Chertow GM, Townsend R, Haley W, Cheung AK, Conroy M, Raj D, Xu D, George T, Younis R, Wei G, Canton MD, Bates J, Chen J, Papademetriou V, Punzi H, Wiggers A, Wright JT, Greene T, Yuan C. Chronic Kidney Disease, Atherosclerotic Plaque Characteristics on Carotid Magnetic Resonance Imaging, and Cardiovascular Outcomes. BMC Nephrol. 2021; 22:69.

97. Ahmad S, Punzi HA, Wright KN, Groban L, Ferrario CM. Newly developed radioimmunoassay for Human Angiotensin-(1-12) measurements in plasma and urine. Mol Cell Endocrinol. 2021; 529:111256.

98. Upadhya B, Pajewski M, Rocco MV, Hundley WG, Aurigemma G, Hamilton CA, Bates JT, He J, Chen J, Chonchol M, Gassler B, Hung AM, Pisoni R, Punzi H, Supiano MA, Toto R, Taylor A, Kitzman D, and the SPRINT Research Group. Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART. Hypertension. 2021; 77(5):1571-1580.

99. Zhang W, Ix J, PunziH, et al. Association of Serum Creatinine Elevations during Follow-up with Subsequent Cardiovascular Disease Events and All-Cause Mortality in SPRINT. Hypertension. 2021.

Clinical Research Trials Completed As Principal Investigator

1. Cilazapril (Inhibace) vs Inderal LA in Essential Hypertension (Protocol N2963A, 1986)

2. Cilazapril + HCTZ in Essential Hypertension (Protocol N3054<A, 1986)

3. Ramipril vs Enalapril Once Daily via 24-hr ABPM (Protocol 354, 1986)

4. CGS 14824A vs Propranolol as Add-on to HCTZ (Protocol GHBA-87, 1987)

5. Captopril vs HCTZ: Quality of Life Effects (Squibb Protocol 12928-245, 1987)

6. Celiprolol Hydrochloride Dose-Response Trial (Protocol RG 5320A-107, 1987)

7. Long-Term Evaluation of RS-10085-197 ACE Inhibitor (Syntex ICM 1534, 1987)

8. Gallopamil-SR Dose-Ranging Trial (Knoll Protocol G-21-HTN, 1988)

9. Long-Term Safety of Gallopamil-SR (Knoll Protocol G-30-HTN, 1988)

10. Diltiazem SR/HCTZ Combination Dose Evaluation (Protocol DZPR0043, 1988)

11. Cardizem SR Safety & Efficacy in Hypertension (Protocol DZPR-0054, 1988)

12. Captopril Modified Release Once Daily Capsules (Protocol 12928-296, 1988)

13. Perindopril Tert-Butylamine Parallel Dose Trial (Protocol PH Phase III, 1988)

14. Perindopril Tert-Butylamine 4-Dose Comparison (Protocol PB, 1988)

15. Zofenopril Twice-Daily Dose Comparison (Protocol 21974-58, 1989)

16. RS-43285-193 Ranolazine in Chronic Stable Angina (Syntex ICM 1513, 1989)

17. Cilazapril High Dose-Response Study (Protocol N3432B, 1989)

18. Diltiazem HCl SR Alone and Concomitant with Indapamide (Protocol RG-83606-105, 1989)

19. Diltiazem C-84 Sustained Release in Stable Angina Pectoris (Protocol 12485, 1989)

20. Isradipine Safety and Efficacy Open-Label Study (Protocol PNH-408, 1989)

21. Nifedipine SR vs Verapamil SR in Hypertension (Protocol D89-023, 1989)

22. Fosinopril vs Verapamil SR on Hemodynamics in Elderly Males (Protocol 23103-80, 1990)

23. Nisoldipine Core-Coat Tablets + Atenolol Combination (Protocol D89-029, 1990)

24. Oral Anipamil vs Isoptin SR in Essential Hypertension (Protocol AN-21-HTN, 1990)

25. Benidipine (KW-3049) Duration of Antihypertensive Effect (Protocol GHBA-340, 1990)

26. Effect of Food on Celiprolol Hydrochloride Efficacy (Protoco] RG 5320A-118, 1990)

27. Trandolapril + Verapamil (Isoptin SR) in Severe Hypertension (Protocol TV-40-HTN, 1991)

28. Adalat SR Substitution for Calan SR in Mild Hypertension (Protocol D90-042, 1991)

29. Cough Profile of Fosinopril Sodium Post-ACE Inhibitor Cough (Protocol CV 119-127, 1992)

30. Nifedipine Coat-Core vs Nifedipine GITS Fasted Study (Protocol D93-032, 1993)

31. SK&F 108566 Dose-Ranging Trial in Essential Hypertension (Protocol SK&F 108566, 1994)

32. BIBR 277 SE Dose Response Trial in Hypertension (Protocol 502.203, 1994)

33. BAY 10-6734 vs Lisinopril in Essential Hypertension (Protocol D94-017, 1995)

34. Trandolapril Added to Verapamil SR in Hypertension (Protocol TV-48-HTN, 1995)

35. PPR Verapamil vs Nifedipine-GITS (Procardia XL) Trial (Protocol N26-94-02-005, 1995)

36. CS-866 ABPM Dose-Ranging Study in Hypertensive Patients (Protocol 866-204, 1995)

37. Atorvastatin vs Simvastatin 54-Week Study in Dyslipidemia (Protocol 981-158, 1996)

38. Glyburide + Troglitazone Glycemic Control Study in T2DM (Protocol 991-085, 1996)

39. CS-866 Long-Term Safety Parallel Study (Protocol 866-305, 1997)

40. CS-866 Long-Term Safety Dose-Titration Study (Protocol 866-306, 1997)

41. SRMoxonidine in Stage 1 & 2 Hypertension (Protocol B3N-MC-EUAT, 1997)

42. Valsartan + HCTZ vs Amlodipine + HCTZ Morbidity Trial (Protocol 405, 1998)

43. Teveten in Isolated Systolic Hypertension (Protocol 145, 1998)

44. Lercanidipine Hydrochloride Dose-Finding Study (Protocol REC 15/2375, 1998)

45. Covera-HS vs Enalapril vs Losartan Study (Protocol N26-98-02-014, 1998)

46. Omapatrilat Response in CCB-Uncontrolled Patients (Protocol CV 137-072, 1999)

47. Micardis (Telmisartan) vs Cozaar (Losartan) ABPM Trial (Protocol 502.343, 1999)

48. Celecoxib Effects on BP in Lisinopril-Controlled Patients (Protocol N49-99-02-048, 1999)

49. Lotrafiban Platelet GP IIb/IIIa Occupancy Study (Protocol SB 214857/030 Bravo, 1999)

50. Irbesartan + Lisinopril Combination PROBE Trial (Protocol BMS 001, 2000)

51. Diltiazem ER (G99) Bedtime vs Morning Dosing in Hypertension (Protocol B00.CT3.011, 2000)

52. Diltiazem ER (G99) Dosing Schedule in Angina Pectoris (Protocol B00.CT3.012, 2000)

53. Natriuretic Peptides in Left Ventricular Dysfunction (Protocol 217242/082, 2000)

54. Valsartan Effect on Heart Rate Variability in Heart Failure (Protocol CVAL489 US12, 2000)

55. ALLHAT Trial: Antihypertensive & Lipid-Lowering Treatment (Protocol ALLHAT, 2000)

56. BiDil Added to Standard Therapy in African-American Heart Failure (Protocol NDA 20-727, 2001)

57. H376/95 Direct Thrombin Inhibitor vs Warfarin in Atrial Fibrillation (Protocol 233, 2001)

58. SAPPHIRE Study: ALT-711 Hemodynamic Elasticity Restoration (Protocol ALT-711-0107, 2001)

59. M100240 Dose-Finding Trial in Essential Hypertension (Protocol M100240/2004, 2001)

60. Lercanidipine Fixed Dose Response Study (Protocol LER-MD-001, 2001)

61. Vitacor Plus & Relacor Study in Stage 1 Hypertension (Protocol MRI-01-001, 2001)

62. Continuous-Combined HRT Blood Pressure Study in Postmenopausal Females (Protocol 305140, 2001)

63. Micardis vs Diovan Post-Missed Dose ABPM Study (Protocol 502.327, 2002)

64. Lotrel vs Amlodipine vs Benazepril SBP Study (Protocol CCIB002FUS08, 2002)

65. Micardis HCT vs Diovan HCT in Obese T2DM Patients (Protocol 502.399, 2002)

66. AVALON Study: Atorvastatin + Amlodipine Dual Therapy (Protocol A3841001, 2002)

67. EXPECT Study: Eprosartan Clinical Trial Open-Label Pilot (Protocol 03BVL001, 2003)

68. Tarka vs Lotrel Albuminuria Trial in T2DM Nephropathy (Protocol M03-599, 2003)

69. Genetic Markers for ACE Inhibitor Angioedema (Protocol AVE7688A/1099, 2003)

70. Celecoxib Analgesic Efficacy in Chronic Low Back Pain (Protocol Coxa-0508-269, 2003)

71. Micardis HCT vs Diovan HCT Trough BP Comparison (Protocol 502.421, 2003)

72. Rosuvastatin (Crestor) Primary Prevention in Low LDL/High CRP (Protocol 4522US/0011, 2004)

73. Sular vs Norvasc Onset Speed Trial (Protocol P45 FH001, 2004)

74. Tarka vs Lotrel COMPARE ABPM Trial (Protocol P45 A001, 2004)

75. Telmisartan/HCTZ vs Valsartan/HCTZ Phase IV Study (Protocol 502.476, 2005)

76. Telmisartan + Amlodipine 4x4 Factorial Design ABPM Trial (Protocol 1235.1, 2005)

77. TBC 3711 Dose-Ranging Study in Resistant Hypertension (2005)

78. Olmesartan Medoxomil/HCTZ vs ACEi/CCB in Stage 2 Hypertension (Protocol 866-447, 2006)

79. 6R-BH4 Effects on BP in Poorly Controlled Hypertension (Protocol HTN-001, 2006)

80. Ramipril + HCTZ Combination vs Monotherapies Study (Protocol K749-06-3001, 2006)

81. Fenofibric Acid + Statin Long-Term Safety Extension (Protocol M05-758, 2006)

82. Fenofibric Acid + Atorvastatin Combination in Mixed Dyslipidemia (Protocol M05-750, 2006)

83. Telmisartan + Amlodipine Factorial Design Trial (Protocol 1236.1, 2006)

84. Olmesartan + Amlodipine Efficacy & Safety Study (Protocol 8663-402, 2007)

85. Nebivolol vs Metoprolol ER in Impaired Glucose Tolerance (Protocol NEB-MD-04, 2007)

86. P5433540 Dual AT/ET Receptor Antagonist Trial (Protocol PCO-C-008, 2007)

87. FAST Tool Validation with Niaspan + Aspirin (Protocol M10-229, 2007)

88. FIRST Trial: Choline Fenofibrate (ABT-335) on CIMT (Protocol M10-158, 2008)

89. Nebivolol vs Carvedilol in CAD & Hypertension (Protocol NEB-MD-06, 2008)

90. Nebivolol Monotherapy in Hispanic Hypertensive Patients (Protocol NEB-MD-16, 2008)

91. Telmisartan/Amlodipine FDC vs Amlodipine in T2DM (Protocol 1235.21, 2009)

92. Alogliptin vs Glipizide + Metformin Durability Study (Protocol SYR-322-305, 2009)

93. Olmesartan Medoxomil vs Losartan Potassium Forced Titration (Protocol CS0886-A-U452, 2009)

94. Darusentan in Resistant Hypertension Extension Study (Protocol DAR-312-E, 2009)

95. Alogliptin CV Outcomes Study in T2DM & Acute Coronary Syndrome (Protocol SYR 322-402, 2009)

96. Nebivolol vs Metoprolol ER vs HCTZ Glycemic Study in T2DM (Protocol NEB-MD-19, 2009)

97. TEAMSTA Trial: Telmisartan/Amlodipine in Severe Hypertension (Protocol 1235.20, 2010)

98. Nebivolol + Lisinopril Combination in Stage 2 Diastolic HTN (Protocol NEB-MD-25, 2010)

99. Nebivolol vs Metoprolol in Subjects Taking Amlodipine (Protocol BYS-MD-48, 2010)

100. CAROLINA Trial: Linagliptin vs Glimepiride Cardiovascular Safety in T2DM (Protocol 1218.74, 2011)

101. ASP1941 SGLT2 Inhibitor Dose-Finding Trial in T2DM (Protocol 1941-CL-0004, 2011)

102. Nebivolol + Valsartan Fixed-Dose Combination Trial (Protocol NAC-MD-01, 2012)

103. Febuxostat 80 mg Effect on ABPM in Hyperuricemia (Protocol TMX-67-206, 2012)

104. Tribenzor Efficacy & Safety 4-6 Week Trial (Protocol PMC-52-005, 2012)

105. Favipiravir Phase 3 Trial in Uncomplicated Influenza (2013)

106. Febuxostat XR vs IR Gout Phase 3 Study (Protocol FEB-XR-301, 2014 & 2015)

107. Empagliflozin in Black/African-American T2DM Patients (Protocol 1245.29, 2014)

108. SPRINT Study (NIH Systolic Blood Pressure Intervention Trial, 2015)

109. PF-04950615 PCSK9 Inhibitor Trial in Hyperlipidemia (Protocol B1481045, 2015)

110. Ramipril + Atorvastatin FDC Pharmacodynamic Equivalence Study (2016)

111. ACT-132577 Endothelin Receptor Antagonist Phase 2 Trial (Protocol AC-080-A201, 2016)

112. ASCENT COPD Study: Aclidinium Bromide CV Safety (Protocol LAS-MD-45, 2016)

113. Nebivolol/Valsartan LVH Study (Protocol BYS-IT-78, 2017)

114. REINFORCE Trial: Renal Denervation using Vessix Catheter (2017)

115. Multicentre Survey of Patients with Treatment-Resistant Hypertension (2017)

116. GALACTIC-HF: Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction (Protocol 20110203, August 3, 2017)

117. SPRINT ASK: Alzheimer's, Seniors, and Kidneys Study (2018)

118. Phase 2b Efficacy and Safety of Oral Insulin ORMD-0801 in Type 2 Diabetes (Protocol ORA-D-015, April 23, 2018)

119. The Chymase Angiotensin-(1-12) Axis in Cardiovascular Disease (Protocol PMC-60-009, 2019)

120. Phase 3 Oral Insulin ORMD-0801 in Type 2 Diabetes on Oral Glucose-Lowering Agents (Protocol ORA-D-013-1, April 7, 2021)

121. FRESH: Firibastat in Difficult-to-Treat/Resistant Hypertension (Protocol QGC001-3QG1, May 4, 2021)

122. Phase 3 Oral Insulin ORMD-0801 in Type 2 Diabetes Managed with Diet or Diet and Metformin (Protocol ORA-D-013-2, June 14, 2022)

123. Advance-HTN: Lorundrostat for Uncontrolled Hypertension (Protocol MLS-101-202, March 27, 2023)

124. Launch-HTN: Lorundrostat for Uncontrolled and Resistant Hypertension (Protocol MLS-101-301, December 6, 2023)

125. HALO: Baxdrostat (CIN-107) in Uncontrolled Hypertension (Protocol CIN-107-124, 2024)

126. BrigHTN: Baxdrostat (CIN-107) in Treatment-Resistant Hypertension (Protocol CIN-107-121, 2024)

127. HALO-OLE: Long-Term Safety and Effectiveness Extension Study of Baxdrostat (Protocol CIN-107-130, 2024)

128. Efficacy and Safety of Inhaled NC-107 versus Placebo in Patients with Anxiety (Protocol NC-65-002, 2024)

129. Transform-HTN: Long-Term Lorundrostat Safety, Efficacy, and Tolerability Extension Study (Protocol MLS-101-901, 2025)

130. Protocol PMC-61-003AZ (2025)

131. ZENITH: Zilebesiran in Inadequately Controlled Hypertension with Cardiovascular Disease or High Cardiovascular Risk (Protocol ALN-AGT01-008, 2026)

132. Efficacy and Safety of lloperidone in Uncontrolled Hypertension (Protocol VP-VYV-683-2401, 2026)

133. Revised Phase 3 Oral Insulin Study in Type 2 Diabetes Inadequately Controlled on One to Three Glucose-Lowering Agents (Protocol ORA-D-013-3, 2026)